Sertaconazole

• UNSPSC Description:

  Sertaconazole (FI7056 free base) is a broad-spectrum topical antifungal agent, exhibits anti-inflammatory activity via activation of a p38-COX-2-PGE2 pathway. Sertaconazole is also a microtubule inhibitor, shows antiproliferative effect, induces apoptosis and autophagy, and can also inhibit the migration of cells[1][2][3][4].

• Target Antigen:

  Apoptosis; Autophagy; Fungal; Microtubule/Tubulin; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Cytoskeleton;MAPK/ERK Pathway

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sertaconazole.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC=C(C(OCC2=CSC3=C(Cl)C=CC=C32)CN4C=CN=C4)C(Cl)=C1

• Molecular Weight:

  437.77

• References & Citations:

  [1]Carrillo-Muñoz AJ, et al. In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. J Antimicrob Chemother. 1995 Oct;36(4):713-6.|[2]Sur R, et al. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J Invest Dermatol. 2008 Feb;128(2):336-44.|[3]Sebastian J, et al. Sertaconazole induced toxicity in HeLa cells through mitotic arrest and inhibition of microtubule assembly. Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1231-1249.|[4]Zhang W, et al. Sertaconazole provokes proapoptotic autophagy via stabilizing TRADD in nonsmall cell lung cancer cells. MedComm (2020). 2021 Dec 16;2(4):821-837.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  99592-32-2